Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
The company will soon be launching a new portfolio of products in this segment
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Subscribe To Our Newsletter & Stay Updated
